The estimated Net Worth of Peter M Hecht is at least $6.27 Million dollars as of 3 June 2021. Peter Hecht owns over 823,170 units of Cyclerion Therapeutics stock worth over $6,153,332 and over the last 15 years he sold CYCN stock worth over $0. In addition, he makes $121,628 as Chief Executive Officer and Director at Cyclerion Therapeutics.
Sign up
Peter Hecht CYCN stock SEC Form 4 insiders trading
Peter has made over 17 trades of the Cyclerion Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 823,170 units of CYCN stock worth $2,699,998 on 3 June 2021.
The largest trade he's ever made was buying 823,170 units of Cyclerion Therapeutics stock on 3 June 2021 worth over $2,699,998. On average, Peter trades about 89,910 units every 74 days since 2010. As of 3 June 2021 he still owns at least 2,047,698 units of Cyclerion Therapeutics stock.
You can see the complete history of Peter Hecht stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Hecht biography
Dr. Peter M. Hecht Ph.D. serves as Chief Executive Officer, Director of the Company. He has served as our chief executive officer and a member of our Board of Directors since we commenced operations as an independent company in April 2019. Dr. Hecht formerly served as the chief executive officer of Ironwood and as a member of its board of directors from its founding in 1998 to March 2019. Under Dr. Hecht's leadership, Ironwood grew into a commercial biotechnology company with over 700 employees, the market-leading IBS-C drug, and five novel drug candidates in clinical development. Prior to founding Ironwood, Dr. Hecht was a research fellow at Whitehead Institute for Biomedical Research. Dr. Hecht serves on the board of Kallyope Inc., a privately held biotechnology company. Dr. Hecht earned a B.S. in mathematics and an M.S. in biology from Stanford University, and a Ph.D. in molecular biology from the University of California at Berkeley.
What is the salary of Peter Hecht?
As the Chief Executive Officer and Director of Cyclerion Therapeutics, the total compensation of Peter Hecht at Cyclerion Therapeutics is $121,628. There are 11 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.
How old is Peter Hecht?
Peter Hecht is 56, he's been the Chief Executive Officer and Director of Cyclerion Therapeutics since 2019. There are 12 older and 2 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.
What's Peter Hecht's mailing address?
Peter's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142.
Insiders trading at Cyclerion Therapeutics
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie, and Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
What does Cyclerion Therapeutics's logo look like?
Complete history of Peter Hecht stock trades at Ironwood Pharmaceuticals Inc and Cyclerion Therapeutics
Cyclerion Therapeutics executives and stock owners
Cyclerion Therapeutics executives and other stock owners filed with the SEC include:
-
Andreas Busch,
Chief Innovation Officer, Head of the Innovation Center -
Dr. Andreas Busch Ph.D.,
Chief Scientific Officer -
Mark Currie,
President, Chief Scientific Officer -
Marsha Fanucci,
Independent Chairman of the Board -
Terrance McGuire,
Independent Director -
Amy Schulman,
Independent Director -
George Conrades,
Independent Director -
Stephanie Lovell,
Independent Director -
Ole Isacson,
Independent Director -
Kevin Churchwell,
Independent Director -
Michael Mendelsohn,
Independent Director -
Peter Hecht,
Chief Executive Officer, Director -
Dr. Peter M. Hecht Ph.D.,
CEO, Interim CFO, Principal Accounting Officer & Director -
William Huyett,
Chief Financial Officer -
Jennifer Chickering,
Sr. Director of Clinical Strategy -
Christopher Winrow,
Sr. Director of Clinical Devel. & Neuroscience Program Lead -
Jessica Rennekamp,
Associate Director of Corp. Communications -
Dr. Todd Milne Ph.D.,
VP of Corp. Devel. -
Cheryl Gault,
Chief Operating Officer -
Anjeza Gjino,
CFO & Corp. Sec. (Maternity Leave of Absence) -
Regina Margaret Graul,
See Remarks -
Path Capital Lp Greenspan D...,
-
Christopher I Wright,
Chief Medical Officer -
Anjeza Gjino,
Chief Financial Officer -
Errol B Desouza,
-
Pharmaceuticals Inc Ironwood,
10% owner -
Cheryl Gault,
Chief Operating Officer -
Steven Hyman,